GlassScriptPhysician profile
Philip C Delich
NPI 1407858889
$2,781.42
in general payments reported to CMS, 2019-2025
16 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $291 · 2021: $159 · 2022: $405 · 2023: $206 · 2024: $378 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $634.77 | 2019-2023 | Mavyret, Skyrizi |
| Cook Medical LLC | $414.28 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.89 | 2019-2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $250.00 | 2024 | |
| Janssen Biotech, INC. | $242.80 | 2019-2025 | Tremfya |
| Boston Scientific Corporation | $232.86 | 2019-2024 | Acquire |
| Gilead Sciences, INC. | $138.64 | 2020-2022 | |
| Exelixis INC. | $134.60 | 2019 | |
| Dova Pharmaceuticals | $115.00 | 2019 | |
| Novo Nordisk INC | $108.47 | 2025 | Wegovy |
| Allergan, INC. | $49.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.82 | 2020-2022 | |
| Braintree Laboratories, INC. | $44.46 | 2019-2024 | Sutab |
| Merck Sharp & Dohme LLC | $25.05 | 2024 | Dificid |
| Ucb, INC. | $23.99 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $19.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Delich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.